Paper Details
- Home
- Paper Details
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].
Author: BruggerW, Deschler-BaierB, FrühM, GautschiO, GriesingerF, KimmichM, LüersA, PirkerR, RadkeS, SchulzC, SebastianM, WiewrodtR, WolfJ
Original Abstract of the Article :
Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) are widely used in non-small cell lung cancer patients harboring activating EGFR mutations. However, resistance mechanisms, particularly the T790 M mutation, hamper longer-term therapeutic success of first and second ge...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1055/a-0647-9835
データ提供:米国国立医学図書館(NLM)
Overcoming Resistance to EGFR-TKI Therapy
In the fight against non-small cell lung cancer, researchers are constantly searching for ways to overcome the challenges posed by drug resistance. This research focuses on the development of third-generation EGFR-TKIs, a new class of drugs designed to combat the T790M mutation, a common mechanism of resistance to first and second-generation EGFR-TKIs. The researchers explore the potential of these new therapies to provide a more effective and sustained treatment for patients with EGFR-mutated lung cancer.
Third-Generation EGFR-TKIs: A New Path in the Desert
This research highlights the promising potential of third-generation EGFR-TKIs, offering hope for patients who have developed resistance to earlier therapies. The researchers found that these drugs demonstrate clinical efficacy, suggesting that they could provide a valuable new weapon in the fight against lung cancer. However, they also emphasize the importance of molecular testing to ensure that patients are appropriate candidates for these therapies.
Personalized Treatment: Navigating the Desert with Precision
This research underscores the importance of personalized medicine, tailoring treatment strategies to the individual needs of each patient. Just as a skilled navigator charts a unique path through the desert, healthcare providers must carefully select the right treatment for each individual. By using molecular testing to identify appropriate candidates for third-generation EGFR-TKIs, we can ensure that patients receive the most effective and targeted therapies.
Dr.Camel's Conclusion
This research offers a glimmer of hope in the desert of lung cancer treatment. The development of third-generation EGFR-TKIs represents a significant step forward in the battle against this challenging disease. By carefully selecting patients and monitoring their responses to these therapies, we can unlock new possibilities for effective and sustained treatment.
Date :
- Date Completed 2019-07-31
- Date Revised 2022-06-03
Further Info :
Related Literature
German
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.